首页> 外文期刊>Applied Microbiology and Biotechnology >M cell-targeting strategy enhances systemic and mucosal immune responses induced by oral administration of nuclease-producing L-lactis
【24h】

M cell-targeting strategy enhances systemic and mucosal immune responses induced by oral administration of nuclease-producing L-lactis

机译:M细胞靶向策略增强了口服核酸酶的L-L-L-乳房诱导的系统性和粘膜免疫应答

获取原文
获取原文并翻译 | 示例
       

摘要

Efficient delivery of antigens to the gut-associated lymphoid tissue (GALT) is the most critical step for the induction of mucosal immunity by oral vaccines. As M cells are the main portal for luminal antigens into the GALT, the M cell-targeting of antigens affords a promising strategy toward the development of effective oral vaccines. Lactococcus lactis is a fascinating recombinant host for oral vaccines, as they survive and produce antigens in the gut and have a particularly safe profile for human use. In this study, we developed and evaluated an M cell-targeting oral immunization system using recombinant L. lactis strains. For the purpose, we generated an L. lactis strain that secretes a model antigen fused with the OmpH 11 domain of Yersinia enterocolitica, which has been shown to bind to a complement C5a receptor on the M cell surface. As the model antigen, Staphylococcus aureus nuclease was used for fusion, resulting in L. lactis-expressing Nuc-OmpH (LL/Nuc-OmpH). Ex vivo intestinal loop assays showed that the amount of Nuc-OmpH taken up into Peyer's patches was more than that of the unfused nuclease (Nuc). In addition, oral administration of the recombinant L. lactis strains to mice demonstrated that LL/Nuc-OmpH-induced nuclease-specific fecal IgA and serum IgG titers were significantly higher than those induced by LL/Nuc. These results indicate that OmpH works as an M cell-targeting molecule when fused with antigens secreted from L. lactis and that the M cell-targeting strategy affords a promising platform for L. lactis-based mucosal immunization.
机译:高效地向肠道相关淋巴组织(GALT)递送抗原是口腔疫苗诱导粘膜免疫的最关键步骤。由于M细胞是腔抗原进入GALT的主要门户,M细胞靶向抗原的靶向为有效口腔疫苗的发育提供了有希望的策略。乳球菌乳酸乳裂是口腔疫苗的迷人重组宿主,因为它们在肠道中存活并产生抗原并具有特别安全的人类使用型材。在该研究中,我们使用重组L.乳酸菌菌株开发并评估了M细胞靶向口腔免疫系统。为目的,我们生成了乳酸乳裂菌菌株,其分泌与yersinia Enterocolitica的OMPH 11结构域融合的模型抗原,这已被证明与M细胞表面上的补体C5a受体结合。作为模型抗原,金黄色葡萄球菌核酸酶用于融合,导致L.乳酸乳酸乳乳酸乳酸乳糖(L1 / Nuc-Omph)。 exVivo肠道循环测定表明,在Peyer的贴片中染色的NUC-OMP照片的量大于未确认的核酸酶(NUC)。此外,对小鼠的重组L.乳酸菌菌株的口服施用证明了LL / NUC-斑诱导的核酸酶特异性粪便IgA和血清IgG滴度显着高于LL / NUC诱导的菌株。这些结果表明,当与从L. Lactis分泌的抗原融合时,OMPH作为M细胞靶向分子融合,并且M细胞靶向策略为L.乳酸乳糜菌的粘膜免疫提供了有希望的平台。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号